Nutanix initiated with a Buy at UBS
UBS analyst Jeff Hickey initiated coverage of Nutanix (NTNX) with a Buy rating and $81 price target The firm sees opportunity ...
West Pharmaceutical upgraded to Buy from Neutral at UBS
UBS upgraded West Pharmaceutical (WST) to Buy from Neutral with a price target of $390, up from $350. The firm has incremental confidence in a positive mix shift driven by Annex 1 regulations, ...
As the Diageo share price flies on a double upgrade is this my last chance to buy it on the ...
The Diageo share price has inflicted plenty of pain on Harvey Jones in 2024, but suddenly it's serving up a large measure of ...
Analysts overhaul Broadcom stock price targets after Q4 earnings
Broadcom CEO Hock Tan gave investors a bullish outlook on the group's potential market for AI chip and networking sales.